These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18079757)

  • 1. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery.
    Wasan KM; Brocks DR; Lee SD; Sachs-Barrable K; Thornton SJ
    Nat Rev Drug Discov; 2008 Jan; 7(1):84-99. PubMed ID: 18079757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs.
    Wasan KM; Cassidy SM
    J Pharm Sci; 1998 Apr; 87(4):411-24. PubMed ID: 9548892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs.
    Patel JP; Brocks DR
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1385-98. PubMed ID: 19663632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophilic drugs and lipoproteins: partitioning effects on chloroethylnitrosourea reaction rates in serum.
    Weinkam RJ; Finn A; Levin VA; Kane JP
    J Pharmacol Exp Ther; 1980 Aug; 214(2):318-23. PubMed ID: 7391979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs.
    Lacko AG; Nair M; Prokai L; McConathy WJ
    Expert Opin Drug Deliv; 2007 Nov; 4(6):665-75. PubMed ID: 17970668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.
    Wasan KM; Lopez-Berestein G
    Arch Med Res; 1993; 24(4):395-401. PubMed ID: 8118164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
    Porter CJ; Trevaskis NL; Charman WN
    Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing transient binding drugs: a new concept for drug discovery.
    Ohlson S
    Drug Discov Today; 2008 May; 13(9-10):433-9. PubMed ID: 18468561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in drug disposition during pregnancy: implications for drug therapy.
    Hodge LS; Tracy TS
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):557-71. PubMed ID: 17696806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of drug metabolism for prediction of intestinal permeability (dagger).
    Chen ML; Yu L
    Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network analysis of adverse drug interactions.
    Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M
    Genome Inform; 2008; 20():252-9. PubMed ID: 19425139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput microsomal stability assay for insoluble compounds.
    Di L; Kerns EH; Li SQ; Petusky SL
    Int J Pharm; 2006 Jul; 317(1):54-60. PubMed ID: 16621364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of parallel chemistry in drug discovery.
    Edwards PJ
    IDrugs; 2006 May; 9(5):347-53. PubMed ID: 16676271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EVolution of research strategies and development in the field of drugs].
    Glomot R
    Ann Pharm Fr; 2000 Jul; 58(4):220-4. PubMed ID: 10915967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of (1)H NMR to facilitate solubility measurement for drug discovery compounds.
    Lin M; Tesconi M; Tischler M
    Int J Pharm; 2009 Mar; 369(1-2):47-52. PubMed ID: 19073245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.